Drug intelligence / Profile preview

xkh001

Development stage: Phase 2
Lead developer: Kanova
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

XKH001 is a recombinant humanized IgG1 monoclonal antibody that specifically inhibits interleukin-25 (IL-25), developed for the treatment of type 2 inflammatory diseases such as asthma and atopic dermatitis. It is administered via subcutaneous injection. Clinical studies have shown favorable safety, pharmacokinetics, and low immunogenicity in healthy subjects. The drug was initially developed by Beijing Kanova Biopharmaceutical Co., Ltd., with ongoing clinical trials in China for moderate to severe asthma and atopic dermatitis[1][2][3].

Other names: Anti-IL-25 monoclonal antibody - Kanova Biopharmaceutical[4]

Targets

IL25 (IL-25)

Beyond the preview

Go deeper on xkh001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xkh001.

Explore the full profile